Intravenous (IV) paracetamol (Perfalgan ® ) is an patients unable to tolerate the oral form when 'nil by mouth', vomiting or with no absorptive capacity.
suggests that in comparison to the oral route it has superior pharmacokinetics 1 1-3 sparing ability (50% vs. oral 30%) 1, 4 . However, there is little information on the new IV paracetamol 5, 6 . The IV form's with greater potential for error, particularly in 5 particularly the risk of hepatotoxicity, as well as IV on their formulary.
representatives. When a new formulary application is
However, when the agent is more costly, has potential Vic. 3052. Anaesthesia and Pain Management, Royal Children's Hospital and Murdoch Childrens Research Institute, and University of Melbourne, Melbourne, Victoria, Australia Although intravenous (IV) paracetamol is an attractive analgesic, there is little information on its paediatric use.
Department of
During an introduction phase with limited prescribing rights, an audit was performed to assess its use and cost impact at a tertiary paediatric centre. This data facilitated our application to extend prescribing rights for IV paracetamol within our institution. As there is limited information or local experience with the use of IV paracetamol in paediatric settings in Australia, our data may be of use to other centres considering the introduction of the IV form of this agent.
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experience' of IV paracetamol use to which we cost impact.
receive surgery with 2350 referrals for acute pain with annotation stating "please specify route", 1.
3.
to receive 1 g 4 to 6 hourly" 5 , as there was concern Data handling/statistical analysis Duration of IV paracetamol 28 6.5 (1, 10.5) 1-33 AUDIT OF PAEDIATRIC IV PARACETAMOL USE Anaesthesia and Intensive Care, Vol. 35, No. 5, October 2007 form of this more costly agent.
prescribing rights to two senior clinicians, who effects. 
